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INTRODUCTION
Amyloidosis is a rare disorder characterized by abnormal, misfolded proteins that accumulate in various organs, causing progressive organ damage [1, 2] . There are several types of systemic amyloidoses; light chain (AL) amyloidosis (Orpha number: ORPHA85443) represents the most common type [3] . The estimated incidence of AL amyloidosis is [8] [9] [10] [11] [12] persons per million per year [4] [5] [6] . In addition, an estimated 10-15% of cases occur in association with multiple myeloma. Based on the incidence data, it is estimated that there are 30,000 to 45,000 patients living with AL amyloidosis in the United States and the European Union.
Clinical presentation of AL amyloidosis can vary widely and depends on the extent and number of organs affected. Initial symptoms at onset are often nonspecific (e.g., weight loss, fatigue). As the disease progresses, symptoms reflect the organs involved, most commonly the heart and the kidneys [5] . The goal of treatment for patients with AL amyloidosis should be to preserve and improve organ function with a well-tolerated and effective disease-modifying therapy. Despite recent advances in AL amyloidosis diagnostic tools and treatment, the early mortality rate remains high; the 1-year mortality rate is approximately 30%.
Unfortunately, by the time a diagnosis is made and treatment is initiated, the disease has often become advanced [4, 5] .
In the absence of approved therapies for AL amyloidosis, physicians use off-label multiple myeloma therapies that target the abnormal plasma cells responsible for the production of the light chain precursor proteins without consideration for the underlying organ dysfunction in the patient [5, 7, 8] . Thus, these treatments can be associated with significant adverse events, and patients often die before experiencing benefit from them [5] . A substantial need remains for well-tolerated and effective therapies that specifically target the underlying cause of the disease: the misfolded light chain proteins.
Despite the significant effects of AL amyloidosis on patient quality of life, data describing them are lacking. Detailing the patient experience may identify ways to improve patient care and disease outcomes.
The primary aim of this study was to gather data on the patient experience to elucidate the challenges in establishing a diagnosis of AL amyloidosis and to gain insight into barriers to accessing appropriate care. 
METHODS

Statistical Analysis
Data were evaluated using descriptive statistics (Microsoft Excel 2013, Redmond, Washington).
Compliance with Ethics Guidelines
This article does not contain information on any new studies in human or animal subjects performed by any of the authors. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients as a condition of their inclusion in the study.
RESULTS
Participants
The initial survey was completed by 533 participants; 57.8% identified themselves as patients, 33.8% identified themselves as family members, and 8.3% identified themselves as caregivers taking the survey on behalf of patients ( Table 1 ). The follow-up survey was completed by 201 participants. Most respondents were female (62.2%) and were between 50 and 69 years of age (62.7%). Table 2) .
Diagnosis of Amyloidosis
Sixty-three percent of respondents had been evaluated at an amyloidosis center (452 total responses), although only 43.7% received treatment at an amyloidosis center (444 total responses).
Amyloidosis Symptoms and Organ
Involvement
The most common initial symptoms were fatigue, shortness of breath, weakness, neuropathy, and swelling of the legs and/or tongue. Most respondents reported the heart (36.7%) or the kidneys (28.1%) as the major organ affected, with involvement of the gastrointestinal tract (5.8%), nervous system (5.5%) or liver (3.2%) reported less frequently ( Table 3 ). Quality of life in patients receiving any of these treatments was greatly improved with treatment for 28.8% of respondents, somewhat improved for 39.1%, and not improved at all for 32.1% (184 total responses). In particular, patients receiving stem cell transplantation rated their quality of life as having improved more substantially than patients receiving other treatments (Table 3) .
Amyloidosis Education
Of the 427 respondents who answered a question pertaining to information or educational material received at the time of diagnosis about their specific amyloidosis type, 39.3% received the center's own printed handouts, 34.4% received another organization's disease or treatment literature, 29.3% received information on support groups, 23.7% received clinical trial information, and 40.0% reported receiving no information or educational material.
Clinical Trial Awareness
In the initial survey, participants were asked to score their answers regarding clinical trial knowledge and access on a scale of 1 to 5, from ''Not at all'' (score 1) to ''Absolutely'' (score 5) (Fig. 2) . A significant number of respondents felt uninformed about clinical trials; 71.6% indicated a score of B3 regarding how knowledgeable they were about clinical trials. Most respondents also felt that they did not have access to pertinent clinical trial information; 68.8% indicated a score of B3 regarding access to clinical trial information. Nevertheless, almost half (46.1%) said they believed that a clinical trial would enhance their medical care (score of C4), and 45.5% reported that they would absolutely consider enrolling in a clinical trial if they were well informed. Forty-six percent of respondents also reported that they did not know how to enroll in a clinical trial. In the follow-up survey, 19.5% of respondents reported that they had participated in a clinical trial (190 total responses). Interestingly, although AL amyloidosis is typically considered to be a disease of the elderly (older than 60 years of age), the median age of respondents in our survey was 57 years, with 34.0% younger than 55 years of age and 15.6% younger than 45 years of age. Despite a selection bias inherent in a web-based survey that may skew to younger persons, younger patients are also probably significantly underdiagnosed.
Considering that 54% of respondents had difficulty in tolerating treatment and only 30% of respondents reported a definite improvement in quality of life, there is a need for therapies clearly associated with treatment benefit. On the other hand, benefits from therapy are more likely to occur in early stages of the disease, making early diagnosis essential for improving outcomes for patients with systemic amyloidosis [11] . Efforts to increase physician awareness of the signs and symptoms and the appropriate evaluation of AL amyloidosis have the potential to improve patient outcomes. We acknowledge the limitations in controlling the quality of information gathered through a web-based questionnaire.
Of note, there is a selection bias inherent to a web-based survey that includes a younger audience of patients and/or younger persons involved in their care. However, we show that this younger population, which likely represents the most knowledgeable segment of patients and which has the best access to Internet resources, is not very well informed. Additionally, there may be a bias with respect to sex given that several studies have shown that men have a higher incidence of most forms of amyloidosis, whereas our respondents were primarily women (62% 
